Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma

被引：9

作者：

Lei, Zhengqing ^{[1
]}

Ma, Weihu ^{[1
]}

Si, Anfeng ^{[2
]}

Zhang, Yuhua ^{[3
]}

Yang, Facai ^{[1
]}

Yu, Qiushi ^{[1
]}

Tang, Haolan ^{[1
]}

Xiao, Qianru ^{[1
]}

Zhou, Jiahua ^{[1
]}

Wang, Kui ^{[4
]}

Tang, Yufu ^{[5
]}

Han, Tao ^{[6
]}

Yin, Guowen ^{[7
]}

Chen, Jinhong ^{[8
,9
]}

Liu, Xiufeng ^{[10
]}

Zhao, Hua ^{[11
]}

Yu, Decai ^{[12
]}

Luo, Tao ^{[13
,14
]}

Wang, Qing ^{[15
]}

Yan, Maolin ^{[16
]}

Mao, Xianhai ^{[17
]}

Li, Jing ^{[18
]}

Wang, Kai ^{[19
]}

Li, Jingdong ^{[20
]}

Zeng, Yongyi ^{[21
]}

Ding, Dequan ^{[22
]}

Chen, Tingsong ^{[23
]}

Wu, Xiaofeng ^{[24
]}

Xia, Yongxiang ^{[24
]}

Wang, Kang ^{[25
]}

Guo, Weixing ^{[25
]}

Zhu, Guangyu ^{[26
]}

Gao, Shan ^{[27
]}

Hueser, Norbert ^{[28
]}

Lau, Wan Y. ^{[29
]}

Song, Tianqiang ^{[30
]}

Cheng, Shuqun ^{[25
]}

Shen, Feng ^{[31
]}

Cheng, Zhangjun ^{[1
]}

机构：

[1] Southeast Univ, Zhongda Hosp, Hepatopancreatobiliary Ctr, Sch Med, Nanjing 210009, Peoples R China

[2] Nanjing Med Univ, Dept Surg Oncol, Qin Huai Med Dist, Jinling Hosp, Nanjing, Peoples R China

[3] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Surg,Inst Basic Med, Hangzhou, Peoples R China

[4] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 2, Shanghai, Peoples R China

[5] Northern Theater Command, Dept Hepatobiliary Surg, Gen Hosp, Shenyang, Peoples R China

[6] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China

[7] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Intervent Radiol Dept,Affiliated Canc Hosp, Nanjing, Peoples R China

[8] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China

[9] Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China

[10] Jinling Hosp, Dept Med Oncol, PLA Canc Ctr, Nanjing, Peoples R China

[11] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou, Peoples R China

[12] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing, Peoples R China

[13] Third Mil Med Univ, Army Med Univ, Inst Pathol, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing, Peoples R China

[14] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Chongqing, Peoples R China

[15] Zibo Cent Hosp, Dept Gen Surg, Zibo, Peoples R China

[16] Fujian Prov Hosp, Dept Hepatobiliary Pancreat Surg, Fuzhou, Peoples R China

[17] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Hepatobiliary Surg, Affiliated Hosp 1, Changsha, Peoples R China

[18] Army Med Univ, Dept Hepatobiliary, Affiliated Hosp 2, Chongqing, Peoples R China

[19] Nanchang Univ, Jiangxi Prov Clin Res Ctr Gen Surg Dis, Dept Gen Surg, Affiliated Hosp 2, Nanchang, Peoples R China

[20] North Sichuan Med Coll, Dept Hepatobiliary Surg, Affiliated Hosp, Nanchong, Peoples R China

[21] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary Surg, Fuzhou, Peoples R China

[22] Maanshan Peoples Hosp, Dept Intervent Radiol, Maanshan, Peoples R China

[23] Shanghai Univ Tradit Chinese Med, Dept Oncol, Peoples Hosp 7, Shanghai, Peoples R China

[24] Nanjing Med Univ, Chinese Acad Med Sci, Hepatobiliary Ctr, Affiliated Hosp 1,Key Lab Liver Transplantat,NHC K, Nanjing, Peoples R China

[25] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China

[26] Southeast Univ, Zhongda Hosp, Ctr Intervent Radiol & Vasc Surg, Sch Med,Dept Radiol, Nanjing, Peoples R China

[27] Southeast Univ, Zhongda Hosp, Adv Inst Life & Hlth, Sch Life Sci & Technol, Nanjing, Peoples R China

[28] Tech Univ Munich, TUM Sch Med, Dept Surg, Klinikum Rechts Isar, Munich, Germany

[29] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[30] Tianjin Med Univ Canc Inst & Hosp, Liver Canc Ctr, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China

[31] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 200438, Peoples R China

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 58卷 / 06期

基金：

中国国家自然科学基金;

关键词：

chemotherapy; combination therapy; immune checkpoint inhibitor; immunotherapy; intrahepatic cholangiocarcinoma; HEPATOCELLULAR-CARCINOMA; OPEN-LABEL; PLUS; BEVACIZUMAB;

D O I：

10.1111/apt.17623

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Immune checkpoint inhibitor (ICI) combination therapy offers a new option for treatment of unresectable intrahepatic cholangiocarcinoma (uICC).Aim: To compare the effect of different anti-PD-1 combination therapies as the first-line treatments for uICC.Methods: This study included 318 patients who received chemotherapy alone (Chemo), anti-PD-1 plus chemotherapy (ICI-chemo), anti-PD-1 plus targeted therapy (ICI-target) or anti-PD-1 plus targeted therapy and chemotherapy (ICI-target-chemo) as first line for uICC from 22 centres in China. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and safety.Results: Patients with ICI-chemo (median PFS [mPFS], 6.3 months; HR: 0.61, 95% CI: 0.42-0.88; p = 0.008; median OS [mOS], 10.7 months; HR: 0.61, 95% CI: 0.39-0.94; p = 0.026), ICI-target (7.2 months; HR: 0.54, 95% CI: 0.36-0.80; p = 0.002; 15.8 months; HR: 0.54, 95% CI: 0.35-0.84; p = 0.006) or ICI-target-chemo (6.9 months; HR: 0.65, 95% CI: 0.47-0.90; p = 0.009; 14.4 months; HR: 0.47, 95% CI: 0.31-0.70; p < 0.001) achieved better clinical outcomes than those with Chemo (3.8 months; 9.3 months). ICI-target was not inferior to ICI-chemo in survival outcomes (HR for PFS: 0.88, 95% CI: 0.55-1.42; p = 0.614; HR for OS: 0.89, 95% CI: 0.51-1.55; p = 0.680). ICI-target-chemo yielded similar prognoses as ICI-chemo (HR for PFS: 1.07, 95% CI: 0.70-1.62; p = 0.764; HR for OS: 0.77, 95% CI: 0.45-1.31; p = 0.328) and ICI-target (HR for PFS: 1.20, 95% CI: 0.77-1.88; p = 0.413; HR for OS: 0.86, 95% CI: 0.51-1.47; p = 0.583) but resulted in more adverse events (p < 0.001; p = 0.010). Multivariable and propensity score analyses supported these findings.Conclusions: Among patients with uICC, ICI-chemo or ICI-target provided more survival benefits than Chemo while achieving comparable prognoses and fewer adverse events than ICI-target-chemo.

引用

页码：611 / 622

页数：12

共 50 条

[31] Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study
Dong, Zhitao
Sui, Chengjun
Lu, Jiongjiong
Guo, Junwu
Duan, Kecai
Wang, Kui
Geng, Li
Dai, Binghua
Yang, Jiamei
FRONTIERS IN IMMUNOLOGY, 2024, 15
[32] The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity
Shah, Jay
Caleb Urias Rivera, Andres
Lee, Irene Jeong-Ah
Takigawa, Kei
Mathew, Antony
Wu, Deanna
Lu, Eric
Shatila, Malek
Thomas, Anusha S.
Zhang, Hao Chi
Altan, Mehmet
Zhao, Dan
Xiao, Qinghuan
Wang, Yinghong
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (03): : 136 - 141
[33] Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor
Cheng, Zhuo
Zeng, Tianmei
Yang, Guang
Liu, Di
Zheng, Zhi
Yuan, Zhengang
LIVER CANCER, 2023, 12 (03) : 281 - 288
[34] Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma
Zeng, Tian-mei
Pan, Yu-fei
Yuan, Zhen-gang
Chen, Dong-sheng
Song, Yun-jie
Gao, Yong
FRONTIERS IN IMMUNOLOGY, 2022, 13
[35] Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real- world study
Ning, Zhouyu
Xie, Lin
Yan, Xia
Hua, Yongqiang
Shi, Weidong
Lin, Junhua
Xu, Litao
Meng, Zhiqiang
BRITISH JOURNAL OF RADIOLOGY, 2023, 96 (1150):
[36] Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?
Elvevi, Alessandra
Laffusa, Alice
Elisei, Federica
Morzenti, Sabrina
Guerra, Luca
Rovere, Antonio
Invernizzi, Pietro
Massironi, Sara
WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1284 - 1293
[37] PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
Liao, Chun-Xu
Deng, Chang-Song
Liang, Xia
Yang, Jian-Chuan
Chen, Zhi-Zhong
Lin, Xiao-Ying
Lin, Cai-Feng
Chen, Shen
Wu, Song-Song
FRONTIERS IN IMMUNOLOGY, 2023, 14
[38] PD-1/PD-L1/CTLA-4 INHIBITOR THERAPY FOLLOWING PROGRESSION ON A DIFFERENT PD-1/PD-L1 INHIBITOR: A CASE SERIES
Mukkamala, Suresh
Tawagi, Karine
Matrana, Marc
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A121 - A121
[39] Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
Peng Yuan
Jinhua Song
Fei Wang
Guangyu Zhu
Baoan Chen
Investigational New Drugs, 2022, 40 : 1125 - 1132
[40] Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
Yuan, Peng
Song, Jinhua
Wang, Fei
Zhu, Guangyu
Chen, Baoan
INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1125 - 1132

← 1 2 3 4 5 →